With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for ...

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Moderna's stock fell Wednesday after Health and Human Services Secretary Robert F. Kennedy Jr. said the department was winding down development of mRNA vaccines.

The US Health Secretary has stopped about $500m worth of funding for the development of vaccines against viruses that cause illnesses like flu and Covid-19. Robert F. Kennedy - a vaccine sceptic - ...

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory ...

This article explains how aluminum adjuvants work in vaccines, their proven safety record, and addresses common myths and ...

The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

On an adjusted basis, Moderna posted a quarterly loss of $2.13 per share, while analysts on average were expecting a loss of ...

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.